AdvaMed, the medical device lobby, pushed back Wednesday on the Trump administration’s weekend firings of Food and Drug Administration employees.
AdvaMed CEO Scott Whitaker sent a letter Tuesday to administrators at the Health and Human Services Department urging them to consider the terminations’ potential ramifications on patient health and medical device innovation. In a call with reporters on Wednesday, he noted that many of the roles were funded, at least in part, by fees paid by device makers to help speed the review of their products. Device companies have already noticed delays, he said.
“We’ve heard from folks who have already gotten notice that current applications may be delayed or suspended,” Whitaker said. “It’s coming in multiple areas.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
